Curasight publishes information memorandum in connection with forthcoming rights issue

COPENHAGEN, Denmark, Feb. 22, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company") (XSAT: CURAS) has prepared and published an information memorandum (the "Information Memorandum") relating to the new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the "Rights Issue"), which was resolved by the Board of Directors on 13 February 2024. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites (www.curasight.com , www.nordic-issuing.se , www.redeye.se).

Summary of the Rights Issue

• Each existing share in the Company, as of the record date on 22 February 2024, entitles the holder to one (1) subscription right. Seven (7) subscription rights entitle the holder to subscribe for one (1) new share at a subscription price of DKK 18 per share.
• The subscription period runs from 23 February 2024, up to and including 7 March 2024.
• The Company's management team, consisting of Ulrich Krasilnikoff (CEO and CFO), Andreas Kjær (CSO/CMO and co-founder) and Hanne Damgaard Jensen (CDO/COO), and members of the Company's Board of Directors, consisting of Per Falholt, Charlotte Vedel, and Kirsten Drejer, have committed to subscribe for shares in the rights issue for a total of approx. DKK 1.7 million, corresponding to 3.4 percent of the rights issue.
• The proceeds are intended to be used to strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, including the preparation, planning and enrolment of the first patients in a therapy phase I/IIa basket trial in various cancer types (brain, neuroendocrine, head and neck, non-small cell lung and pancreatic cancer), as well as to strength Curasight's pipeline through development of new peptide-based radioligand therapies.

Information Memorandum

Full terms and conditions for the Rights Issue as well as other information about the Company and further information about subscription commitments, is included in the Information Memorandum. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites (www.curasight.com, www.nordic-issuing.se, www.redeye.se). Subscription forms will be available on the Company's, Nordic Issuing AB's, and Redeye AB's respective websites.

Timetable for the Rights Issue

Advisors

Redeye AB is acting as a financial advisor to Curasight. DLA Piper Denmark Advokatpartnerselskab is acting as the legal adviser of Curasight. VP Euronext Securities A/S is the Company's issuing agent and Nordic Issuing is acting as the settlement agent.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: [email protected]
www.curasight.com

The following files are available for download:

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED